These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31847174)

  • 21. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible.
    Engelhardt M; Kortüm KM; Goldschmidt H; Merz M
    Haematologica; 2024 Aug; 109(8):2420-2435. PubMed ID: 38356448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.
    Mailankody S; Kazandjian D; Korde N; Roschewski M; Manasanch E; Bhutani M; Tageja N; Kwok M; Zhang Y; Zingone A; Lamy L; Costello R; Morrison C; Hultcrantz M; Christofferson A; Washington M; Boateng M; Steinberg SM; Stetler-Stevenson M; Figg WD; Papaemmanuil E; Wilson WH; Keats JJ; Landgren O
    Blood Adv; 2017 Oct; 1(22):1911-1918. PubMed ID: 29296837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
    Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O
    Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Requirements for operational cure in multiple myeloma.
    Mohty M; Avet-Loiseau H; Harousseau JL
    Blood; 2021 Oct; 138(16):1406-1411. PubMed ID: 34324647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roadmap to cure multiple myeloma.
    Rodriguez-Otero P; Paiva B; San-Miguel JF
    Cancer Treat Rev; 2021 Nov; 100():102284. PubMed ID: 34597912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
    Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
    Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma.
    Wang J; Li J; Zhang R; Li J; Chen L; Jin Y
    Discov Oncol; 2024 Feb; 15(1):38. PubMed ID: 38367151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
    de Tute RM; Pawlyn C; Cairns DA; Davies FE; Menzies T; Rawstron A; Jones JR; Hockaday A; Henderson R; Cook G; Drayson MT; Jenner MW; Kaiser MF; Gregory WM; Morgan GJ; Jackson GH; Owen RG
    J Clin Oncol; 2022 Sep; 40(25):2889-2900. PubMed ID: 35377708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
    San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
    Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
    Lahuerta JJ; Paiva B; Vidriales MB; Cordón L; Cedena MT; Puig N; Martinez-Lopez J; Rosiñol L; Gutierrez NC; Martín-Ramos ML; Oriol A; Teruel AI; Echeveste MA; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Martin A; Alegre A; De la Rubia J; Orfao A; Mateos MV; Blade J; San-Miguel JF;
    J Clin Oncol; 2017 Sep; 35(25):2900-2910. PubMed ID: 28498784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost.
    Suzuki K
    Int J Hematol; 2020 Apr; 111(4):512-518. PubMed ID: 32125606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
    Fonseca R; Arribas M; Wiedmeier-Nutor JE; Kusne YN; González Vélez M; Kosiorek HE; Butterfield RDJ; Kirsch IR; Mikhael JR; Stewart AK; Reeder C; Larsen J; Bergsagel PL; Fonseca R
    Blood Cancer J; 2023 Mar; 13(1):32. PubMed ID: 36878906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.
    Royle KL; Coulson AB; Ramasamy K; Cairns DA; Hockaday A; Quezada S; Drayson M; Kaiser M; Owen R; Auner HW; Cook G; Meads D; Olivier C; Barnard L; Lambkin R; Paterson A; Dawkins B; Chapman M; Pratt G; Popat R; Jackson G; Bygrave C; Sive J; de Tute R; Chantry A; Parrish C; Cook M; Asher S; Yong K
    BMJ Open; 2022 Nov; 12(11):e063037. PubMed ID: 36396306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.
    Kunacheewa C; Lee HC; Patel K; Thomas S; Amini B; Srour S; Bashir Q; Nieto Y; Qazilbash MH; Weber DM; Feng L; Orlowski RZ; Lin P; Manasanch EE
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):e221-e238. PubMed ID: 32037287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in minimal residual disease monitoring in multiple myeloma.
    Wijnands C; Noori S; Donk NWCJV; VanDuijn MM; Jacobs JFM
    Crit Rev Clin Lab Sci; 2023 Nov; 60(7):518-534. PubMed ID: 37232394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
    Anderson KC; Auclair D; Adam SJ; Agarwal A; Anderson M; Avet-Loiseau H; Bustoros M; Chapman J; Connors DE; Dash A; Di Bacco A; Du L; Facon T; Flores-Montero J; Gay F; Ghobrial IM; Gormley NJ; Gupta I; Higley H; Hillengass J; Kanapuru B; Kazandjian D; Kelloff GJ; Kirsch IR; Kremer B; Landgren O; Lightbody E; Lomas OC; Lonial S; Mateos MV; Montes de Oca R; Mukundan L; Munshi NC; O'Donnell EK; Orfao A; Paiva B; Patel R; Pugh TJ; Ramasamy K; Ray J; Roshal M; Ross JA; Sigman CC; Thoren KL; Trudel S; Ulaner G; Valente N; Weiss BM; Zamagni E; Kumar SK
    Clin Cancer Res; 2021 Oct; 27(19):5195-5212. PubMed ID: 34321279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.
    Biran N; Ely S; Chari A
    Curr Hematol Malig Rep; 2014 Dec; 9(4):368-78. PubMed ID: 25224462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.
    Guerrero C; Puig N; Cedena MT; Goicoechea I; Perez C; Garcés JJ; Botta C; Calasanz MJ; Gutierrez NC; Martin-Ramos ML; Oriol A; Rios R; Hernandez MT; Martinez-Martinez R; Bargay J; de Arriba F; Palomera L; Gonzalez-Rodriguez AP; Mosquera-Orgueira A; Gonzalez-Perez MS; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; Mateos MV; San-Miguel JF; Paiva B
    Clin Cancer Res; 2022 Jun; 28(12):2598-2609. PubMed ID: 35063966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.